
Epizyme (NASDAQ:EPZM) brought in sales totaling $8.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.58%, resulting in a loss of $55.51 million. Epizyme collected $11.58 million in revenue during Q4, but reported earnings showed a $50.65 million loss.